45
https://pubmed.ncbi.nlm.nih.gov/38091543
The reply by Wharton and Konig discusses the potential benefits and limitations of the GLP-1 receptor agonist Orforglipron for weight management in adults with obesity, as reported in a recent New England Journal of Medicine study.
